당뇨병성 신경병증 치료 시장 예측(-2030년) : 유형별, 치료법별, 약물 종류별, 유통 채널별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Diabetic Neuropathy Treatment Market is accounted for $4.6 billion in 2023 and is expected to reach $7.6 billion by 2030 growing at a CAGR of 7.5% during the forecast period. Diabetic neuropathy treatment is the various medical interventions and lifestyle modifications aimed at managing the symptoms and complications of neuropathy caused by diabetes. It is a type of nerve damage that can result from prolonged high blood sugar levels associated with diabetes. The treatment approach typically involves a combination of medications, lifestyle changes, and sometimes alternative therapies to alleviate pain, improve nerve function, and prevent further nerve damage.

According to National Diabetes Statistics Report by the Centers for Disease Control and Prevention (CDC), it was found that 34.2 million U.S. individuals (10.5% of the U.S. population) were clinically diagnosed with diabetes in 2018.

Market Dynamics:

Driver:

Rising prevalence of diabetes

With more individuals being diagnosed with diabetes, the demand for effective neuropathy treatments has increased significantly. This trend is driven by factors such as lifestyle changes, aging populations, and heightened awareness leading to early diagnosis. As a result, pharmaceutical companies and healthcare providers are focusing more resources on developing and providing innovative solutions to address diabetic neuropathy. Thus, the market is experiencing a notable surge due to the rising prevalence of diabetes.

Restraint:

Limited efficacy of treatments

Despite advancements, treatments for diabetic neuropathy face challenges, with limited efficacy remaining a significant concern. Current therapies often focus on symptom management rather than addressing the underlying causes. This limitation underscores the need for continued research and innovation in the market to develop more effective strategies that target the root mechanisms of neuropathy in diabetic patients.

Opportunity:

Advancements in treatment

Innovative therapies like nerve decompression surgery, regenerative medicine using stem cells, and targeted drug delivery systems are emerging. Moreover, non-invasive techniques like neurostimulation and wearable tech for continuous monitoring show promise. Precision medicine tailoring treatments to individual genetic profiles is another frontier. These developments signify a shift towards more effective, personalized, and holistic approaches in managing diabetic neuropathy.

Threat:

High cost of treatments

With treatments often priced beyond affordability, access to essential therapies becomes restricted, exacerbating the burden on individuals already grappling with the challenges of managing diabetes-related neuropathy. This financial strain underscores the pressing need for interventions aimed at making these treatments more accessible and affordable to ensure comprehensive care for those affected by diabetic neuropathy. Therefore, the market is plagued by exorbitant costs, creating barriers for patients seeking care.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Diabetic Neuropathy Treatment market. Delays in diagnosis and treatment due to healthcare resource reallocation led to worsening patient conditions. Telemedicine gained prominence for consultations, while disruptions in the pharmaceutical supply chain affected medication availability. Clinical trials and research also faced setbacks, slowing down the development of new treatment options.

The focal neuropathy segment is expected to be the largest during the forecast period

The focal neuropathy segment is expected to be the largest during the forecast period. Current therapies include pain management medications, physical therapy, and lifestyle modifications to control blood sugar levels. Emerging treatments such as nerve stimulation techniques and regenerative medicine show promise in addressing underlying nerve damage. However, personalized approaches tailored to individual patient needs remain a key area of research to optimize outcomes in this challenging aspect of diabetic neuropathy management.

The clinics segment is expected to have the highest CAGR during the forecast period

The clinics segment is expected to have the highest CAGR during the forecast period. These clinics provide a range of services, including diagnostic testing, medication management, physical therapy, and lifestyle counseling. They employ skilled healthcare professionals such as neurologists, endocrinologists, and physical therapists who work collaboratively to develop personalized treatment plans. These clinics aim to improve patients' quality of life by managing symptoms, preventing complications, and promoting overall well-being.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Key players are focusing on developing innovative therapies to address the unmet needs of patients. Additionally, favorable reimbursement policies and healthcare infrastructure are contributing to market expansion. With ongoing research and development activities, the market is poised for continued growth and is expected to offer lucrative opportunities for stakeholders.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to various factors such as the increasing prevalence of diabetes. The market offers a range of treatment options for diabetic neuropathy, including medications, physical therapy, nerve stimulation techniques, and lifestyle modifications. Pharmaceutical companies are actively developing new drugs and therapies to address this condition. Technological advancements in medical devices and diagnostics have also contributed to the growth of the market.

Key players in the market

Some of the key players in Diabetic Neuropathy Treatment market include GlaxoSmithKline Plc, Lupin Ltd, Depomed, Inc, Astellas Pharma Inc, Meda Pharma GmBH & Co. KG, Glenmark Pharmaceuticals Ltd., Eli Lilly and Company, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Pfizer Inc., Novo Nordisk A/S, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Novartis AG, Asprius Lifesciences, and Vertex Pharmaceuticals.

Key Developments:

In December 2023, Vertex Pharmaceuticals received FDA approval for CRISPR-based gene editing therapy, a strategy focused on developing and promoting non-opioid pain relievers Based on Vertex's Phase 2 clinical trial results for VX-548, highlighting alternative pain management strategies in diabetic peripheral neuropathy Thiah of the safe and consistent with the search for more effective treatments.

In July 2023, Asprius Lifesciences recently started treating diabetic neuropathy, a disease that causes nerve damage in different parts of the body the company has filed patents for a patented drug combination (FDC), indicating potential for peripheral nerve block.

Types Covered:

• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy
• Peripheral Neuropathy
• Other Types

Treatments Covered:

• Slow Progression of Diseases
• Pain Relieving
• Managing Complications
• Physiotherapy
• Drugs
• Other Treatments

Drug Classes Covered:

• Non-Steroidal Anti-Inflammatory Drugs
• Opioid
• Anti-Depressants
• Anti-Seizure
• Other Drug Classes

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics

End Users Covered:

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Homecare Settings
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Diabetic Neuropathy Treatment Market, By Type

• 5.1 Introduction
• 5.2 Autonomic Neuropathy
• 5.3 Proximal Neuropathy
• 5.4 Focal Neuropathy
• 5.5 Peripheral Neuropathy
• 5.6 Other Types

6 Global Diabetic Neuropathy Treatment Market, By Treatment

• 6.1 Introduction
• 6.2 Slow Progression of Diseases
• 6.3 Pain Relieving
• 6.4 Managing Complications
• 6.5 Physiotherapy
• 6.6 Drugs
• 6.7 Other Treatments

7 Global Diabetic Neuropathy Treatment Market, By Drug Class

• 7.1 Introduction
• 7.2 Non-Steroidal Anti-Inflammatory Drugs
• 7.3 Opioid
• 7.4 Anti-Depressants
• 7.5 Anti-Seizure
• 7.6 Other Drug Classes

8 Global Diabetic Neuropathy Treatment Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Hospital Pharmacies
• 8.3 Retail Pharmacies
• 8.4 Online Pharmacies
• 8.5 Specialty Clinics

9 Global Diabetic Neuropathy Treatment Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Clinics
• 9.4 Ambulatory Surgical Centers
• 9.5 Homecare Settings
• 9.6 Other End Users

10 Global Diabetic Neuropathy Treatment Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 GlaxoSmithKline Plc
• 12.2 Lupin Ltd
• 12.3 Depomed, Inc
• 12.4 Astellas Pharma Inc
• 12.5 Meda Pharma GmBH & Co. KG
• 12.6 Glenmark Pharmaceuticals Ltd.
• 12.7 Eli Lilly and Company
• 12.8 Abbott Laboratories
• 12.9 F. Hoffmann-La Roche Ltd
• 12.10 Johnson & Johnson
• 12.11 Pfizer Inc.
• 12.12 Novo Nordisk A/S
• 12.13 Merck & Co., Inc.
• 12.14 Teva Pharmaceutical Industries Ltd.
• 12.15 AbbVie Inc.
• 12.16 Novartis AG
• 12.17 Asprius Lifesciences
• 12.18 Vertex Pharmaceuticals